Teleflex delivered 32% revenue growth year-over-year and has beaten earnings in 3 of the last 4 quarters, but negative price momentum with a momentum score of only 2.8 out of 10 and falling on-balance-volume signal active distribution, while the stock already sits near its analyst-implied ceiling with negative upside asymmetry.
Thesis pillars
- Revenue Growth Leadership→Stable
- Earnings Beat With One Large Miss→Stable
- Negative Price Momentum Distribution↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Teleflex Incorporated (TFX) Stock Analysis
Range Bound setup · Catalyst-Driven edge
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $131.05, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative momentum.
Teleflex designs and supplies single-use medical devices for critical care and surgical applications across Americas, EMEA, and Asia Pacific segments. Revenue comes from selling Arrow-branded catheters, intraosseous systems, interventional cardiology devices, and surgical... Read more
Hold if already holding. Not a fresh buy at $131.05, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Mixed signals. Hold existing position. Score 6.1/10, moderate confidence.
Passes 3/7 gates (clean insider activity, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-07-28Recent Developments — Teleflex Incorporated
Latest news
- NEWS Teleflex Inc. stock outperforms competitors on strong trading day - MarketWatch — MarketWatch positive
- NEWS TFX Maintained by Mizuho -- Price Target Raised to $145 - GuruFocus — GuruFocus positive
- NEWS Teleflex (NYSE:TFX) Price Target Raised to $145.00 at Mizuho - MarketBeat — MarketBeat positive
- NEWS Mizuho Securities Maintains Teleflex(TFX.US) With Hold Rating, Raises Target Price to $145 - Moomoo — Moomoo positive
- NEWS TFX Stock Down Post Q1 Earnings & Revenue Beat, Margins Crash - TradingView — TradingView positive
Generated 2026-07-31T02:43:38Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-30Item 5.02MEDIUMJason Weidman appointed as President and CEO effective June 8, 2026, replacing interim CEO Stuart A. Randle, who continues as a Board member. Weidman joins from Medtronic.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $131.05, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Negative momentum. Chart setup: RSI 46 mid-range, Bollinger mid-band. Mixed signals. Hold existing position. Target $136.40 (+4.1%), stop $122.43 (−7.0%), A.R:R -0.3:1. Score 6.1/10, moderate confidence.
Take-profit target: $136.40 (-1.9% upside). Target $136.40 (+4.1%), stop $122.43 (−7.0%), A.R:R -0.3:1. Stop-loss: $122.43.
Analyst target reached - limited upside remaining; Negative momentum.
Teleflex Incorporated trades at a P/E of 1872.1 (forward 12.4). TrendMatrix value score: 6.5/10. Verdict: Hold.
17 analysts cover TFX with a consensus score of 3.5/5. Average price target: $148.
What does Teleflex Incorporated do?Teleflex designs and supplies single-use medical devices for critical care and surgical applications across Americas,...
Teleflex designs and supplies single-use medical devices for critical care and surgical applications across Americas, EMEA, and Asia Pacific segments. Revenue comes from selling Arrow-branded catheters, intraosseous systems, interventional cardiology devices, and surgical products to hospitals worldwide through a direct sales force and distributors. In December 2025, Teleflex announced $2.0 billion in pending divestitures of its Acute Care, Interventional Urology, and OEM businesses.